Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
News|Articles|April 4, 2024
Is 2024 the Year for Psychedelic Medicine?
Author(s)Ashley Gallagher, Editor
MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.
Advertisement
Advertisement
Psychedelic therapy might be closer to reality than previously thought, with big movements in 2024 for midomafetamine capsules (MDMA)-assisted therapy and a separate adjunct treatment with psilocybin for mental health disorders. MDMA-assisted therapy from Lykos Therapeutics is being evaluated in combination with psychological interventions, which include psychotherapy and other services from a health care provider, for posttraumatic stress disorder (PTSD). CYB003 (Cybin), a psilocybin compound, is being evaluated as an adjunctive treatment for major depressive disorder.1,2
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Advertisement
Advertisement